Patent SG-11201901993S-A (SG)
Title: Use of recombinant lymphocyte activation gene-3
Inventor: RODRIGUEZ OQUENDO ANNABELLE
IPC: G01N33/92
Filed: 2017-09-12
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property :::` , Organization MD 1101111 0 DOI HIM 011101 0 011111111111111111111111111111111111111111111 International Bureau (10) International Publication Number 03 (43) International Publication Date .....•\"\" WO 2018/049410 Al 15 March 2018 (15.03.2018) WIP0 I PCT (51) International Patent Classification: G01N 33/92 (2006.01) Published: — with international search report (Art. 2 1 (3)) (21) International Application Number: — before the expiration of the time limit for amending the PCT/US2017/051210 claims and to be republished in the event of receipt of (22) International Filing Date: amendments (Rule 48.2(h)) 12 September 2017 (12.09.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 15/262,618 12 September 2016 (12.09.2016) US (72) Inventor; and (71) Applicant: RODRIGUEZ OQUENDO, Annabelle [US/US]; 79 Bradford Walk, Farmington, CT 06032 (US). (74) Agent: CRAIG, Royal, W.; Baker, Donelson, Beaman, Caldwell & Berkowitz, PC, 100 Light Street, 19th Floor, Baltimore, MD 21202 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). = (84) 1-1 ..! (54) Title: USE OF RECOMBINANT LYMPHOCYTE ACTIVATION GENE-3 0 (57) : A method for classifying patients at risk for cardiovascular disease, other chronic inflammatory diseases, cardiovascular 1-1 iv and/or non-cardiovascular morbidity and mortality based on a risk assessment for lymphocyte activation gene 3 (LAG3) protein defl- Of ciency, and for mediating the risk using recombinant lymphocyte activation gene-3 or LAG3 mimetic as a companion therapeutic alone 71' or in combination with a statin and/or an anti-hyperlipidemic drug, The risk assessment is two-prong, beginning with a qualitative de- 0 --.... termination whether a subject has of is predisposed to abnormal expression of inflammasomes, heightened risk for inflammation and/or 0 1-1 0 to dysfunctional HDL, followed, by a quantitative assay or genetic screen for a polymorphism that occurs in the coding sequence of the O LAG3 gene. Given positive indication, recombinant LAG3 and/or LAG3 mimetic is used alone or in combination with the therapeutic ei use of a cholesterol mediating, drug for treatment. C